Latest News

Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.

The newly launched units will be deployed across Ranchi, Kanpur, Bhopal, Jaipur, and Bhubaneswar.

The therapy, known as NRTX-1001, uses pluripotent stem cells engineered to regulate brain activity and repair damaged neural networks.

Under the agreement, Stereotaxis will pay USD20 million upfront, with up to an additional USD25 million tied to milestone-based payments.

The Phase Ib/II trial will assess safety, tolerability, and early signs of clinical activity. Researchers will combine Boehringer Ingelheim’s investigational T-cell engager, obrixtamig, with Zai Lab’s antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci).

The company grew revenue by 10% to EUR 1.75 billion (USD1.91 billion) while substantially improving profitability and cash generation.

For Daiichi Sankyo, divesting this business allows the company to concentrate resources on its innovative medicines division, where it has emerged as a leader in antibody-drug conjugate (ADC) technology.

The Verida system represents a leap forward in CT imaging, incorporating Philips’ third-generation Nano-panel Precise dual-layer detector alongside an AI-driven deep learning reconstruction engine.

The European Medicines Agency rejected Elevidys for ambulatory patients last year, citing insufficient evidence of effectiveness.

The partnership leverages the EAEA’s scientific expertise with Alameda Healthcare’s clinical and operational capabilities to create a sustainable, patient-centered treatment hub.